|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NEUROPHARMACOLOGY
-Amyloid-Induced Neurodegeneration and Protection by Structurally Diverse Microtubule-Stabilizing Agents
Department of Pharmacology and Toxicology (M.L.M., S.A., Y.C., K.I.S.), Department of Medicinal Chemistry (E.R.R., G.I.G.), Department of Molecular Biosciences (R.H.H.), and Department of Pharmaceutical Chemistry (K.L.A.), University of Kansas, Lawrence, Kansas
Deposition of
-amyloid peptide (A
) and hyperphosphorylation of the
protein are associated with neuronal dysfunction and cell death in Alzheimer's disease. Although the relationship between these two processes is not yet understood, studies have shown that both in vitro and in vivo exposure of neurons to A
leads to
hyperphosphorylation and neuronal dystrophy. We previously reported that the microtubule-stabilizing drug paclitaxel (Taxol) protects primary neurons against toxicity induced by the A
25-35 peptide. The studies in this report were undertaken to characterize the actions of paclitaxel more fully, to assess the effectiveness of structurally diverse microtubulestabilizing agents in protecting neurons, and to determine the time course of the protective effects of the drugs. Primary neurons were exposed to A
in the presence or absence of several agents shown to interact with microtubules, and neuronal survival was monitored. Paclitaxel protected neurons against A
1-42 toxicity, and paclitaxel-treated cultures exposed to A
showed enhanced survival over A
-only cultures for several days. Neuronal apoptosis induced by A
was blocked by paclitaxel. Other taxanes and three structurally diverse microtubule-stabilizing compounds also significantly increased survival of A
-treated cultures. At concentrations below 100 nM, the drugs that protected the neurons did not produce detectable toxicity when added to the cultures alone. Although multiple mechanisms are likely to contribute to the neuronal cell death induced by oligomeric or fibrillar forms of A
, low concentrations of drugs that preserve the integrity of the cytoskeletal network may help neurons survive the toxic cascades initiated by these peptides.
Address correspondence to: Dr. M. L. Michaelis, Department of Pharmacology and Toxicology, 1251 Wescoe Hall Dr., 5064 Malott Hall, University of Kansas, Lawrence KS 66045. E-mail: mlm{at}ku.edu
This article has been cited by other articles:
![]() |
A. Pannaccione, F. Boscia, A. Scorziello, A. Adornetto, P. Castaldo, R. Sirabella, M. Taglialatela, G. F. D. Renzo, and L. Annunziato Up-Regulation and Increased Activity of KV3.4 Channels and Their Accessory Subunit MinK-Related Peptide 2 Induced by Amyloid Peptide Are Involved in Apoptotic Neuronal Death Mol. Pharmacol., September 1, 2007; 72(3): 665 - 673. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Asuni, A. Boutajangout, D. Quartermain, and E. M. Sigurdsson Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements J. Neurosci., August 22, 2007; 27(34): 9115 - 9129. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Masters and K. Beyreuther Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the A{beta} amyloid pathway Brain, November 1, 2006; 129(11): 2823 - 2839. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Q. Trojanowski and V. M.-Y. Lee The Alzheimer's Brain: Finding Out What's Broken Tells Us How to Fix It Am. J. Pathol., November 1, 2005; 167(5): 1183 - 1188. [Full Text] [PDF] |
||||
![]() |
J. M. Gerdes and N. Katsanis Small molecule intervention in microtubule-associated human disease Hum. Mol. Genet., October 15, 2005; 14(suppl_2): R291 - R300. [Abstract] [Full Text] [PDF] |
||||